6-K 1 d932055d6k.htm 6-K 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of February 2025

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒  Form 40-F

 

1


In February 2025, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated herein by reference.

Exhibit Index

 

Exhibit No.

  

Description

Exhibit 99.1    Press Release dated February  22, 2025 : ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
Exhibit 99.2    Press Release dated February 25, 2025 : Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: February 28, 2025       SANOFI     
    By    /s/ Alexandra Roger                      
      Name: Alexandra Roger
      Title: Head of Legal Corporate & Finance

 

3